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Lachlan A. Jolly 1✉, Euan Parnell 2, Alison E. Gardner1, Mark A. Corbett 1, Luis A. Pérez-Jurado 1,3,4,5, Marie Shaw1,
Gaetan Lesca6,7, Catherine Keegan8, Michael C. Schneider9, Emily Griffin10, Felicitas Maier11, Courtney Kiss12, Andrea Guerin13,
Kathleen Crosby14, Kenneth Rosenbaum14, Pranoot Tanpaiboon14, Sandra Whalen15, Boris Keren16, Julie McCarrier17, Donald Basel17,
Simon Sadedin18,19,20, Susan M. White18,19,20, Martin B. Delatycki18,19,20, Tjitske Kleefstra21, Sébastien Küry 22,23, Alfredo Brusco 24,25,
Elena Sukarova-Angelovska26, Slavica Trajkova24, Sehoun Yoon2, Stephen A. Wood 27, Michael Piper28,29, Peter Penzes2 and
Jozef Gecz 1,4✉
USP9X is an X-chromosome gene that escapes X-inactivation. Loss or compromised function of USP9X leads to neurodevelopmental
disorders in males and females. While males are impacted primarily by hemizygous partial loss-of-function missense variants, in
females de novo heterozygous complete loss-of-function mutations predominate, and give rise to the clinically recognisable USP9X-
female syndrome. Here we provide evidence of the contribution of USP9X missense and small in-frame deletion variants in USP9X-
female syndrome also. We scrutinise the pathogenicity of eleven such variants, ten of which were novel. Combined application of
variant prediction algorithms, protein structure modelling, and assessment under clinically relevant guidelines universally support
their pathogenicity. The core phenotype of this cohort overlapped with previous descriptions of USP9X-female syndrome, but
exposed heightened variability. Aggregate phenotypic information of 35 currently known females with predicted pathogenic
variation in USP9X reaffirms the clinically recognisable USP9X-female syndrome, and highlights major differences when compared
to USP9X-male associated neurodevelopmental disorders.
npj Genomic Medicine            (2020) 5:53 ; https://doi.org/10.1038/s41525-020-00162-9
INTRODUCTION
The deubiquitylating enzyme encoded by USP9X is best known for
its roles in brain development and cancer1. It is ranked among the
top 5% of evolutionary constrained genes and is highly intolerant
to variation (pLI= 1.0; z-score= 6.35)1–4. It is essential for
embryonic viability5. USP9X functions to reverse the effects of
protein ubiquitylation, a frequent post-translational modification
that often culminates in protein degradation via the proteasome6.
USP9X thus protects many of its substrates from degradation,
thereby increasing their abundance and hence function1. Many
USP9X substrates are encoded by genes involved in brain
development and neurodevelopmental disorders (NDDs)1.
Furthermore, rare USP9X mutations have been identified to
directly cause NDDs7–10.
USP9X is located on the X-chromosome. The inheritance
patterns and clinical presentations of the X-linked disorders
often differ between males and females. X-linked disorders
predominantly affect hemizygous males while female carriers
are generally unaffected. This was the case for the historical family
MRX99, with multiple affected males, in which a C-terminal
protein truncating variant in USP9X was maternally transmitted
across three generations8. An additional 15 likely pathogenic
missense variants have since been reported in affected males,
with further 26 of uncertain significance (VUS)7,8. Many of these 42
variants were inherited through unaffected mothers, while others
arose de novo. We showed that these male USP9X missense
variants cause partial, rather than complete loss of USP9X
function7,8,11. In particular, these mutations disable brain-specific
USP9X functions, while leaving other functions, such as those
essential for embryonic viability, intact.
Sparing of heterozygous females in X-linked disorders may
involve protective X-inactivation. USP9X is, however, an atypical
X-chromosome gene which escapes X-inactivation, and thus the
likely mechanisms is also related to its gene expression and as
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such dosage10. Nonetheless, the USP9X mutations found in the
affected females are predominantly complete loss of function
(LOF) alleles. In total, 20 females have been reported with a
syndromic NDD, also known as MRX99F, caused by de novo
heterozygous USP9X null mutations including whole and partial
gene deletions, nonsense and early frameshift mutations10,12–14.
Studies using patient derived cells established that these LOF
mutations caused reduction of USP9X mRNA and protein
abundance in affected females, suggesting haploinsufficiency as
a likely disease mechanism. Such LOF alleles are likely to never be
observed in a male as complete loss of USP9X, as would be the
case of a hemizygous male, is known to result in early embryonic
lethality in at least mouse5.
USP9X is significantly depleted of missense variants, which
would indicate that at least some of these variants are likely highly
deleterious to USP9X function, e.g. when located in critical
domains of the protein. Indeed, a single missense mutation
altering a residue in the catalytic domain of USP9X has been
identified in a female individual with strong clinical resemblance
to others with USP9X-female syndrome10. In this report, we
identify and study an additional 10 novel female variants, 8
missense and 2 in-frame single amino acid deletions. In depth
comparative in silico predictions and structural modelling pro-
vided support of pathogenicity. We also assess and compare the
clinical presentations of this cohort against all reported individuals
with USP9X-female syndrome. We define an expanded and
overlapped phenotypic spectrum of these female cohorts, which
collectively revealed similarities and differences in the phenotypic
features observed in male versus female USP9X associated NDDs.
Collectively, our data expands the mutational mechanisms and
phenotypic outcomes relating to USP9X-female syndrome.
RESULTS
Identification of novel USP9X variants in affected females
Following our earlier reports of USP9X variants in male and female
cases with NDDs8,9, we have collected, through international
clinical, diagnostic and research centres, several additional female
ascertained USP9X variants of unknown clinical significance. As
part of this study we have further selected and scrutinised eight
missense variants and two in-frame single amino acid deletions.
These variants were predominantly identified using trio based
exome sequencing (Table 1; Supplementary Data). In addition to
these 10 novel variants we also analysed one previously reported
missense variant (Female 8; ref. 10).
One of the variants (p.Asp1685Asn) was found in two unrelated
individuals (Females 26 and 27). In Female 26, this variant was
inherited from a mosaic mother (de novo in mother). A second
inherited variant in Female 33 (p.Glu1764Lys) was also passed on
from the mother, but intriguingly with no evidence of mosaicism,
at least in blood (Table 1 and Supplementary Data). This variant
was not found in the maternal grandmother, while the maternal
grandfather (with no signs of disability) could not be tested. The
other nine of eleven variants all arose de novo (Supplementary
Data). Applying the guidelines of the American College of Medical
Genetics Guidelines (ACMG; ref. 15) we classified all of these 11
variants as likely pathogenic (Table 1 and Supplementary Data). All
were also predicted to be deleterious using Polyphen216 and
Combined Annotation Dependent Depletion (CADD; ref. 17)
algorithms (Table 1 and Supplementary Data). All 11 variants alter
highly conserved amino acids, all but one invariable (Fig. 1a).
These variants are novel and not present in Genome Aggregation
Database (gnomAD V2.1.1;18) consisting of >140,000 exomes or
genomes (Table 1). In general, the variants impacted regions of
the USP9X protein, which were predicted to be intolerant to
variation (Fig. 1b; ref. 19). Five of the variants were located in the
ubiquitin C hydrolase (UCH) catalytic domain, while the others
were found distributed in the N-terminal extension of the protein
of largely unknown structure and function (Table 1 and Fig. 1b). To
see if these variants clustered in potential USP9X ‘mutation
hotspots’, we compared their location with those of likely
pathogenic variants associated with male NDDs (n= 16; ref. 7).
Furthermore, as USP9X loss-of-function mutations are also
enriched in somatic cancers1, we included variants extracted from
the Catalogue of Somatic Mutations in Cancer (COSMIC) database
that are predicted to be deleterious (CADD score >30; n= 49).
While this analysis did not reveal any striking variant ‘hotspots’, we
noted that the catalytic domain was potentially enriched with
female variants, and enriched with cancer variants, compared to
its flanking regions (p= 0.08 and p= 0.00017 respectively via two-
proportion z-test; Fig. 1b).
Table 1. Details of USP9X missense and single amino acid deletion variants associated with USP9X-female syndrome.
Case ID cDNA Protein Catalytic domain Diagnostic test Inheritance gnomaD ACMG Polyphen_2 CADD
Female 21 c.671 T > C p.Leu224Pro No DES De novo 0 LP D 29.9
Female 22 c.1073 T > A p.Val358Asp No WES–Trio De novo 0 LP D 26.4
Female 23 c.1303 T > C p.Trp435Arg No WES–Trio De novo 0 LP P 27.1
Female 24 c.3664 G > C p.Ala1222Pro No WES–Trio De novo 0 LP D 29.5
Female 25 c.3986 G > A p.Arg1329His No WES–Trio De novo 0 LP D 32
Female 34 c.4147_4149delCTT p.Leu1383del No WES–Trio De novo 0 LP n/a 21.3
Female 26 c.5053 G > A p.Asp1685Asn Yes WES–Trio Maternala 0 LP D 29.7
Female 27 c.5053 G > A p.Asp1685Asn Yes WES–Trio De novo 0 LP D 29.7
Female 8 c.5078 T > G p.Leu1693Trp Yes WES–Trio De novo 0 LP D 28.7
Female 33 c.5290 G > A p.Glu1764Lys Yes WES–Trio Maternalb 0 LP D 32
Female 28 c.5405 A > G p.Tyr1802Cys Yes WES–Trio De novo 0 LP D 29.9
Female 29 c.5642_5644delATT p.Tyr1881del Yes WES–Trio De novo 0 LP n/a 22.4
cDNA coordinates are given in reference to NM_001039590.2 and protein coordinates in reference to NP_001034679.2.
DES disease exome sequencing,WES–Trio whole-exome sequencing in Trio, gnomAD Genome Aggregation Database V2.1.1, ACMG American College of Medical
Genetics classification15 where LP stands for likely pathogenic; Polyphen_2 represents prediction based on HDIV scores where D: damaging and P: possibly
damaging; Combined Annotation Dependent Depletion (CADD) scores are given where CADD >20 equates to the top 1% of deleterious variants17. n/a not
available.
aMaternal germline mosaic.
bNon mosaic (at least in blood).
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Fig. 1 Conservation and protein location of likely pathogenic USP9X-female variants. a Cross species protein alignment of USP9X showing
conservation of altered amino acid residues. b Location of female likely pathogenic variants on the USP9X protein structure. USP9X variation
tolerance landscape is provided (see Materials and Methods). Locations of male likely pathogenic variants and predicted deleterious missense
somatic cancer variants (extracted from COSMIC database with CADD score ≥30) are shown for comparison.
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Altogether we identify 10 novel female USP9X missense and
single amino acid deletion variants associated with NDDs, which
alter generally invariable amino acids and are located in protein
regions required for catalytic activity and/or intolerant to variation.
Variant prediction algorithms support pathogenicity of
USP9X-female missense variants
To extend our investigations into the functional (or not) effect of
these variants, we employed an array of in silico missense variant
pathogenicity predictive tools. We compared the outcomes of
these predictive algorithms between the female likely pathogenic
missense variants and that of common (i.e. assuming to be
benign) USP9X missense variants. We defined a common variant
as one with an allele frequency >1:100,000 in the gnomAD V2.1.1
database (n= 159)18. The gnomAD derived variants are from
individuals devoid of severe paediatric disease, and are found
distributed throughout the entire protein (including catalytic
domain and regions predicted intolerant to variation). They
provide the best, currently available control dataset to further
interrogate the pathogenicity of USP9X variation (Supplementary
Fig. 1). We submitted all missense variants, including common
variants, female and male NDD variants, and all COSMIC variants
(n= 358; Supplementary Fig. 1) to the suite of variant prediction
tools within the ANNOVAR ensemble20. We previously established
several tools with the best predictive power for assessing USP9X
missense variation7. Using these same tools, we compared the
combined predictive scores of the USP9X common variants with
the female, male and cancer variants. For each tool used (CADD,
Ployphen2, M-CAP, Mutation Assessor, VEST3, DANN, SIFT and
PROVEAN), female missense variants scored significantly higher
than common variants, thus supporting pathogenicity (Fig. 2a).
The scores of female variants also trended higher than male
variants, and that of cancer, suggesting that on average they were
more deleterious. We have also reported beforehand that a
combined score of CADD and PROVEAN provides a highly
stringent predictive rubric for USP9X missense variation7. Applying
this approach, we found 100% of these nine female missense
variants tested were scored as pathogenic (CADD > 25 and
PROVEAN > 0.5665) compared to 75% of male likely pathogenic
variants, 45% of cancer variants and only 15% of common variants
(Fig. 2b). Thus, several in silico predictive approaches provided
congruent support of the pathogenicity of female USP9X likely
pathogenic missense variants.
Protein structure modelling of the USP9X catalytic domain variants
We employed our recently resolved USP9X UCH catalytic domain
structural model7,11 to interrogate the molecular mechanisms
underpinning pathogenicity of the five female missense and
single amino acid deletion variants found within (Table 1 and
Fig. 3). Notably, the predicted effects of missense variation using
this structural model thus far have been validated using in vitro
recombinant protein binding and deubiquitinating assays11. The
p.Tyr1881 residue deleted in Female 29 contributes to a beta-
sheet critical for the positioning of the UCH catalytic triad. The
p.Tyr1881 deletion is predicted to alter the position of the catalytic
residue p.His1879 and likely to have significant effects on catalytic
activity. Predicted deleterious cancer variants (i.e. CADD > 30) in
close proximity (p.Ser1872Asn, p.Ala1875Val, p.Ser1876Gly,
p.Val1870Ile) likely act via similar mechanisms (Fig. 3). The
p.Tyr1802 residue altered in Female 28 contributes to the
hydrophobic surface involved in ubiquitin binding via interaction
with the p.Ile36 residue of ubiquitin. The p.Tyr1802Ser substitution
introduces a polar amino acid predicted to disrupt the hydro-
phobicity and ubiquitin binding. Predicted deleterious cancer
variants (p.Lys1798Thr, p.Arg1799Gln, p.Arg1799Leu) are pro-
posed to have similar effect (Fig. 3). The p.Asp1685Asn substitu-
tion in Female 27 also results in an amino acid charge reversal, and
is predicted to alter the intramolecular charge–charge interaction
with p.Gln1796, and as such constrict the ubiquitin binding
channel and sterically clash with the backbone amine of the
p.Leu73 residue of ubiquitin. This mechanism is similar to that
predicted for proximal deleterious cancer variants (p.Glu1688Lys,
p.Glu1688Ala; Fig. 3). The p.Leu1693Trp variant in Female 8
introduces a highly bulky tryptophan predicted to disrupt the local
hydrophobic core provided by p.Val1643, p.Leu1647, p.Phe1689
and p.Phe1671. The importance of maintaining this fold is
highlighted by the presence of predicted deleterious cancer
variants acting via similar mechanism (p.Ser1692Leu and
p.Val1694Met; Fig. 3). The p.Glu1764Lys variant in Female 33 lies
within the zinc finger motif of the catalytic domain, which forms
multiple contacts with ubiquitin and is integral to the catalytic
activity of several related deubiquitinating enzymes21,22. Indeed,
structure based mutations of USP9X which disrupt zinc-binding
alter its activity towards specific types of ubiquitin chain
linkages23, while the presence of multiple deleterious cancer
variants (p.Asp1761Tyr, p.Asp1720Asn and p.Arg1783Cys) in the
zinc finger motif provide additional support of its importance.
Thus while p.Glu1764Lys is surface exposed and not likely to be
involved in stabilizing intramolecular interactions, its close
proximity to the zinc-binding site suggests it may alter the
positioning or zinc-binding properties of this motif, suggesting
profound effect on USP9X ubiquitin chain specificity and activity23.
Thus structural modelling of the all likely pathogenic USP9X-
female variants located in the catalytic domain provides rationale
for disrupted catalytic activity and/or ubiquitin binding, and is
supported by analogous mechanisms of several proximal pre-
dicted deleterious variants arising in cancer.
Variable phenotype of females with USP9X missense variants
All females in our missense and single amino acid deletion cohort
(n= 12) were ascertained primarily on the basis of psychomotor
developmental delay (Fig. 4a and Supplementary Data). Intellec-
tual disability (ID) was present in all individuals where assessed,
but was variable, ranging from borderline to severe. All individuals
displayed problems with speech and language, the severity of
which was also across a wide spectrum, ranging from somewhat
innocuous delay through to complete absence. There was also
variable effects on the development of motor function, ranging
from unreported to severe disability, which in two individuals
required standing supports or wheel chairs. Motor disability was
most frequently related to hypotonia (Fig. 4a). Hearing loss was a
prominent feature, and individuals displayed a number of
different behavioural disturbances including autism, anxiety and
aggression (Fig. 4a and Supplementary Data). All individuals
presented with brain malformations, most frequently agenesis of
the corpus callosum and ventriculomegaly (Fig. 4a, b and
Supplementary Data). Other congenital abnormalities were also
observed, involving skeletal defects affecting the spine, feet and
hips, and heart defects, the latter of which resulted in neonatal
lethality in one case (Female 23; Supplementary Data). In addition,
abnormalities affecting skin, gastroenterological, urogenital, meta-
bolic and endocrine systems were observed at lower frequencies
(Supplementary Data). Facial dysmorphisms were prevalent in
almost all individuals, and was in close alignment with previously
reported individuals with USP9X-female syndrome, with common
features including deep-set eyes, telecanthus, blepharophimosis,
broad nasal tip with wide alae and short collumnella, low set and
dysplastic ears, small mouth and micrognathia (Fig. 4a, c,
Supplementary Fig. 2 and ref. 10). These data reveal a variable
phenotype associated with missense and single amino acid
deletion USP9X variants in females, with major features of
developmental delay, ID, speech and motor delay, prevalent brain
malformations and other congenital aspects particularly affecting
the development of the craniofacial structures spine and heart.
L.A. Jolly et al.
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Affected females share key clinical presentations, which differ in
USP9X males
We also sought to establish if the clinical presentations of our
female cohort with missense and single amino acid deletion
variants overlapped with those of previously reported individuals
with USP9X-female syndrome caused by bona fide complete loss
of function alleles. For this purpose we combined the phenotypic
information from the 20 reported individuals with heterozygous
Fig. 2 USP9X-female missense variants display in silico signatures of pathogenicity. a Aggregate comparison of common variants extracted
from gnomAD (allele frequency >1:100000), against females missense variants, likely pathogenic male missense variants, and variants found in
cancer (extracted from COSMIC database) using a suite of in silico prediction tools. Box-whisker plots are defined as follows: centre line,
median; box limits, upper and lower quartiles; whiskers, min and max values. *significantly different from common variants p < 0.05 by two-
tailed equal variance Student’s t-test. b Comparison of CADD and PROVEAN scores reveal clustering of variants all female missense variants in
the upper-right quadrant consistent with pathogenicity (CADD > 25, PROVEAN > 0.565). Scores of common variants are significantly correlated
(Pearson’s correlation given). Colour scheme as in a. Inset identifies each variant in the ‘pathogenic quadrant’. Graphs show percent of each
type of variant, and the overall composition of variant types within the pathogenic quadrant.
L.A. Jolly et al.
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gene deletion, nonsense and frameshift USP9X alleles (Supple-
mentary Fig. 3; refs. 10,12–14). We herein further expand this cohort
by reporting an additional three novel cases (Females 30–32;
Fig. 5a, b, Supplementary Fig. 2). These individuals presented with
phenotypes that also highlight the range of severities associated
with USP9X variation (Supplementary Data). Female 30 had a de
novo nonsense variant (p.Trp380Ter) and presented with severe
ID, absent speech and severe motor disability. In comparison,
Female 32 with a de novo frameshift variant (p.Ile535Asnfs*11) had
only slight delays in speech, language and motor skills, and is now
largely meeting developmental milestones. Furthermore a mater-
nally inherited nonsense variant (p.Arg215Ter) was found follow-
ing the genetic autopsy of Female 31, a terminated foetus with
brain malformation, heart and skeletal defects (Supplementary
Data). In this instance, while the mother was assessed as having a
history of scoliosis and partial hearing impairment, she was
otherwise normal and with no dysmorphic features or additional
congenital anomalies. These cases further expand the clinical
spectrum associated with bona fide heterozygous loss of function
USP9X variants.
We then combined phenotypical data from all such individuals
(n= 23; Supplementary Fig. 3) and compared the frequency of
major clinical features to that observed in the female individuals
harbouring missense and single amino acid deletion variants (n=
12 cases; Supplementary Data). We found strong concordance in
the prevalence of combined neurological and other congenital
features between these cohorts (Fig. 5c). These data strongly
support the pathogenicity of missense and single amino acid
deletion variants in females.
Given this strong overlap, we combined data from both these
two female cohorts (n= 23+ 12= 35 individuals) to best define
the clinical presentations in females with deleterious USP9X
Fig. 3 Structural modelling of USP9X-female variants located in the catalytic domain. a Homology model of USP9X (grey) with catalytic site
(magenta), likely pathogenic female variants (red) and location of predicted deleterious cancer variants (blue; extracted from COSMIC
database with CADD score >30). Interaction with ubiquitin is shown. Likely pathogenic variants are positioned in regions of well‐ordered
secondary structure or flexible regions involved in zinc-binding. b Insets indicate local structural effects of indicated likely pathogenic female
USP9X variants. All native amino acid side chains are represented as grey sticks. Variant amino side chains are indicated by red sticks. Side
chains of the amino acids forming the core catalytic site are indicated by magenta sticks. Location of cancer variants is highlighted in blue.
Zinc ion is represented with a yellow sphere. Hydrophobic van der vaals radii are indicated by dots and charge–charge interactions are shown
by dotted lines.
L.A. Jolly et al.
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variants (Fig. 5c). Subsequently, we also used this data to compare
females with males (n= 167) with pathogenic or likely pathogenic
USP9X variants (Fig. 5d). While the major neurological findings
were similar between males and females, males were unlikely to
have congenital presentations including skeletal and heart
defects, among others (Fig. 5d). These data also support the
deleterious effect of the UPS9X missense and single amino acid
deletion variants, refine USP9X-female syndrome phenotype from
an aggregate of 35 individuals, and point to major differences
between males and females with USP9X variants.
DISCUSSION
Here we expand the genotypic and phenotypic spectrum of USP9X-
female syndrome. The current state of knowledge suggests that de
novo heterozygous complete LOF USP9X variants cause a defined
syndrome in heterozygous females10. Twenty-three such females
have been now been reported, including the three novel cases
herein. These female LOF mutations include whole or partial gene
deletions, early nonsense and frameshift mutations10,12–14. Males
with such LOF mutations are unlikely to survive early stages post
fertilisation5. Here we present new evidence that missense and
single amino acid deletion variants can also cause a similar female
phenotype. Prior to this study, only a single affected female
missense variant located in the USP9X catalytic domain had been
reported10. We now add 10 additional variants classified as likely
pathogenic under the ACMG guidelines, shedding new light into the
genetic origin of USP9X disease as well as its clinical presentations.
Eight of these 10 novel variants occurred de novo in these
females, which by a traditional view could also have been
Fig. 4 Phenotypic features of females with USP9X missense and single amino acid deletion variants. a Constellation and frequency of
major clinical features. b Magnetic resonance imaging (MRI) of brains of affected individuals. Note prominent extra-axial spaces in all,
hypoplastic corpus callosum in Females 25 and 29, optic nerve atrophy and in Female 25, Dandy Walker malformation and Blake’s pouch cyst
in Female 26, and ventriculomegaly of the 3rd and 4th ventricles in Female 29. c Images of affected females showing facial dysmorphisms,
with common features including deep-set eyes, telecanthus, blepharophimosis, a broad nasal tip with wide alae and short collumnella, and
low set and dysplastic ears. Written consent was obtained for the publication of photographs.
L.A. Jolly et al.
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considered an ‘incidental finding’ of an USP9X unaffected carrier
female. One individual had an inherited variant from their mother
who were subsequently found to be mosaic, a mode which has
been previously reported10. The remaining case of Female 33, with
a variant inherited from her unaffected mother, who is unlikely a
somatic mosaic, suggests possible modifier(s) of female pene-
trance, perhaps similar to e.g. the X-chromosome linked PCDH19
clustering epilepsy24. While it is also plausible to question this
specific USP9X variant’s pathogenicity, the variant is located within
the catalytic domain, it is predicted to be pathogenic universally
by several algorithms, and the affected girl bears clear clinical
resemblance to USP9X-female syndrome. That includes cardinal
clinical presentations such as skin pigmentation, hip dysplasia,
heart defects, choanal atresia and hearing loss in addition to other
hallmark neurological and craniofacial features. We also identified
another similar transmission, in a case of a maternally inherited
nonsense variant (Female 31). In this instance the LOF effect of
this variant (p.Arg215*) is highly likely. The carrier mother of this
child had a history of scoliosis, but was otherwise unaffected.
These two cases of variable penetrance of USP9X LOF variants in
heterozygous females suggest the existence of a disease modifier.
One possible candidate is skewing of X-inactivation, but USP9X is
known to escape X-inactivation. That said, the degree to which a
gene escapes from X-inactivation is known to be variable, and can
be tissue specific25–28. Complete skewing of X-inactivation may
also suggest the existence of another genetic abnormality on one
of the X-chromosomes of the affected female, which can be
contributing to the phenotype independently of USP9X, e.g. as has
been observed in an affected female carrier of Fragile X29.
Furthermore, a haploinsufficiency-like mechanism of USP9X-
female NDD is not supported by e.g. phenotypes observed in
Turner Syndrome with XO sex chromosome karyotype, which
generally lack neurological manifestations30. Possible role for
X-inactivation in USP9X-female NDDs is suggested by several
Fig. 5 Comparison of phenotypic features of females with different USP9X variant types and with males. a Location of bona fide loss-of-
function variants in individuals with USP9X-female syndrome. Three novel variants described in this study are annotated. b Images showing
facial dysmorphisms of females affected by novel nonsense and frameshift USP9X variants. Note resemblance to individuals in Fig. 4c.
c Comparison of clinical features of females with missense and single amino acid deletions (n= 12) variants with females harbouring null
alleles including all previously published cases and three novel cases identified in this study (n= 23). Sankey plot highlights overlap across all
features except short stature. d Comparison of clinical features of a combined female cohort (n= 35) with phenotypes of all published males
with likely pathogenic variants (n= 16). Sankey plot highlights overlap across neurological features but not in other major female associated
congenial phenotypes. Thickness of each stream is proportional to the percentage of cases with each feature, which is also provided
numerically at the terminal nodes.
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frequently observed clinical features including mosaic skin
pigmentations and asymmetries in brain formation, breast
development, limb development and other structures10,12,13.
Previous studies have however shown that skewing of
X-inactivation in DNA obtained from three out of five patient
derived fibroblasts showed no correlation with disease severity10.
However, as it is also the case in e.g. PCDH19 clustering epilepsy,
where the blood or skin-derived X-inactivation is not informa-
tive31, mouse model evidence suggests that it is at play in at least
brain32. X-inactivation studies revealed no evidence of skewing in
Female 33, whilst studies on the mothers DNA were uninformative
across multiple loci (data not shown). We were also unable to
conduct further studies on Female 31 and her mother. Other
potential modifiers may relate to specific variants, such as
interindividual variation in nonsense mediated mRNA decay33 or
associated transcriptional compensation34,35. Thus examples and
identification of USP9X variants with variable penetrance offer an
opportunity to investigate the likely modifiers and their mechan-
ism in a deeper and more systematic manner.
The set of major clinical features of USP9X-female syndrome
associated with de novo heterozygous gene deletion, nonsense
and frameshift mutations involves developmental delay, ID, brain
malformations and other congenital abnormalities impacting
craniofacial development, and the heart, skeleton, skin and other
organs10. These clinical presentations were also observed in our
cohort of females with missense and single amino acid deletion
USP9X variants, but which also appeared variable. Variability in
female USP9X associated NDDs can also be driven by the
underlying mutation type and not just existence of modifiers (as
discussed above). All previously reported mutations result in a loss
of USP9X dosage10, with likely downstream impact on all USP9X
substrates. This uniform molecular mechanism was proposed to
underpin the consistency in the phenotypic outcomes shared
among different individuals giving rise to the reports of a
recognisable USP9X-female syndrome. Furthermore, genetic abla-
tion of Usp9x from the developing mouse brain (loss of dosage)
provides a strong recapitulation of the neurological phenotypes of
these affected females, including hypoplastic corpus callosum,
ventriculomegaly, and learning and memory problems7,11,36,37.
The impact of missense mutations is less defined, and may cause
differential impact on downstream substrates and as such
phenotypic outcome(s). The variants affecting the catalytic
domain are most likely similar to complete LOF alleles, whilst
those in the N-terminal extensions may disrupt only subsets of
USP9X substrates (see below). It is yet to be determined as to
whether these missense variants retain residual USP9X function or
act as dominant negative alleles.
The affected female missense and single amino acid deletion
variants we identified in this study all passed through rigorous in
silico testing which further supported pathogenicity. Detailed
structural modelling of the five variants impacting the catalytic
domain supplied evidence of altered catalytic activity and/or
binding to ubiquitin. This was reinforced by the presence of
multiple likely deleterious cancer variants (CADD > 30) in close
proximity, which were projected to act via overlapping mechan-
isms. USP9X is a known tumour suppressor38–40 and there also
exists a significant enrichment of LOF USP9X variants in the
COSMIC database1. It is noteworthy that childhood malignancy
has been reported in two female individuals with USP9X-female
syndrome10, and could potentially be involved in the natural
course of the condition. The other variants were all located in the
N-terminal region of largely undetermined function1. Male USP9X
variants in the N-terminal regions have been shown to disrupt
subsets of USP9X substrate interactions, rather than all7. These
substrates are, however, critical specifically for the function of
neurodevelopmental signalling pathways TGFβ, mTOR, Notch and
Wnt7, all of which have been shown to be deregulated in the
developing brains of mice lacking Usp9x11,37,41–43. It was also
striking to see that males shared much of the neurological
phenotypical features shared in our female cohorts, but almost
none of the other congenital features. At least some of these male
variants are inherited from phenotypically normal mothers, and as
such likely better tolerated in a heterozygous state. The female
missense mutations reported herein the N-terminal region of
USP9X are speculated to be more deleterious than their male
counterparts, disrupting more critical (but unknown) USP9X
functions or overall USP9X protein structural integrity. On
aggregate, the outcomes of the in silico predictive tools not only
supported the pathogenicity of the female variants, but also
showed that they were more deleterious than male variants. This
is a preliminary finding and requires larger validation datasets.
Highly deleterious variants are unlikely to ever be identified in
males due to probable effect on embryonic viability5,37. It was
notable that the mosaic mother of Female 26 (p.Asp1685Asn) had
a history of five miscarriages.
In conclusion, in this study we identified likely pathogenic
missense and single amino acid deletion variants, and additional
nonsense and frameshift variants in USP9X in affected hetero-
zygous females. The phenotype of these females affirmed that of
previous reports, but also highlighted its considerable variability.
Our study thus reveals the complexities in the clinical definition,
and genetic aetiology of an emerging USP9X-female syndrome.
METHODS
Subjects
This study was approved by the Women’s and Children’s Health Network
Human Research Ethics Committee, South Australia, Australia
(HREC786–07–2020). All subject information was provided following
informed guardian consent. The authors affirm that guardians of human
research participants provided written informed consent for publication of
images in Figs. 4 and 5 and Supplementary Fig. 2.
Variant analysis
Two-proportion z-test for enrichment of variants in the catalytic domain
was conducted using http://www.sthda.com/english/wiki/two-proportions-
z-test-in-r where full length USP9X is 2570 amino acids in length and
catalytic domain is 396 amino acids in length. Variant predictions were
performed using Annovar20 accessed via the webserver http://wannovar.
wglab.org/. Box-whisker plots are defined as follows: centre line, median;
box limits, upper and lower quartiles; whiskers, min and max values.
Statistical significance was assessed using two-tailed equal variance
Student’s t-test with p < 0.05. USP9X tolerance to variation landscape was
established using methods described in ref. 19 and outputted using the
Metadome Version 1.0.1 webserver at https://stuart.radboudumc.nl/
metadome/dashboard.
Structural modelling
The USP9X catalytic structural homology model was generated and
characterized using Maestro Prime module (Schrodinger, LLC, NY, USA)
using the crystal structure 5WCH (http://www.rcsb.org/structure/5WCH)
with absent flexible loop regions modelled ab initio through energy
minimization7,11,44. Homology model image generation and mutagenesis
were performed using PyMol V1.8.2.0 (Schrodinger).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
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reasonable request, subject to compliance with our obligations under human
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